Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
CHAMPIONS ONCOLOGY, INC. (CSBR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/15/2023 |
8-K
| Quarterly results |
| 12/13/2022 |
8-K
| Quarterly results |
| 09/08/2022 |
8-K
| Quarterly results |
| 03/15/2022 |
8-K
| Quarterly results |
| 12/13/2021 |
8-K
| Quarterly results |
| 09/13/2021 |
8-K
| Quarterly results |
| 09/14/2017 |
8-K
| Quarterly results |
| 03/16/2017 |
8-K
| Form 8-K - Current report |
| 11/29/2016 |
8-K
| Form 8-K - Current report |
| 09/09/2016 |
8-K
| Quarterly results |
| 07/28/2016 |
8-K
| Form 8-K - Current report |
| 03/15/2016 |
8-K
| Form 8-K - Current report |
| 12/14/2015 |
8-K
| Quarterly results |
| 09/10/2015 |
8-K
| Quarterly results|
Docs:
|
"Champions Oncology Reports Results for the First Quarter Ended July 31, 2015 Hackensack, NJ – September 10, 2015 – Champions Oncology, Inc. , engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2015. First Quarter and Recent Business Highlights: • Completed uplisting to NASDAQ Capital Market • Filed patent applications to develop humanized mice to be used in immune-oncology • Announced additions to management team Joel Ackerman, Champions Oncology CEO, stated, “We continue to make progress in building the company. As the recognition of the value of patient derived xenografts grows, we are being presented with many opportunities to expand ..." |
|
| 07/28/2015 |
8-K
| Quarterly results|
Docs:
|
"Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 Hackensack, NJ – July 28, 2015 – Champions Oncology, Inc. , engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2015. Fourth Quarter and Recent Business Highlights: • Quarterly revenue increased 32% over the same prior year period result • Procured a quarterly record high of more than 140 implants Joel Ackerman, Champions Oncology CEO, stated, “The end of fiscal 2015 is an opportune time to assess the accomplishments and challenges of the past year. While the Company experienced an anticipated slowdown in revenue growth in the earlier part of the year, the foundatio..." |
|
| 03/17/2015 |
8-K
| Quarterly results|
Docs:
|
"Champions Oncology Reports Results for the Third Quarter Ended January 31, 2015 Hackensack, NJ – March 17, 2015 – Champions Oncology, Inc. , engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third quarter ended January 31, 2015. Third Quarter and Recent Business Highlights: • Completed $14 Million Capital Raise • Signed 31 new TOS studies from existing and new customers • Procured a quarterly record 55 implants from research collaborations Joel Ackerman, Champions Oncology CEO, stated, “We continue to make progress in building our TumorGraft platform and executing our strategy. Bookings in the core TOS business were strong for a second consecutive quarter as a resu..." |
|
| 12/12/2014 |
8-K
| Quarterly results |
| 09/11/2014 |
8-K
| Quarterly results |
| 07/24/2014 |
8-K
| Quarterly results |
| 03/13/2014 |
8-K
| Quarterly results |
| 07/28/2010 |
8-K
| Form 8-K - Current report |
| 09/17/2009 |
8-K
| Quarterly results |
| 07/30/2008 |
8-K
| Form 8-K - Current report |
|
|